Literature DB >> 19305158

Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.

Yungan Tao1, Céline Leteur, Ceyao Yang, Ping Zhang, Maria Castedo, Alain Pierré, Roy M Golsteyn, Jean Bourhis, Guido Kroemer, Eric Deutsch.   

Abstract

Checkpoint kinase-1 (CHK1) is a key regulator of the DNA damage-elicited G(2)-M checkpoints. The aim of the present study was to investigate the effects of a selective CHK1 inhibitor, Chir124, on cell survival and cell cycle progression following ionizing radiation (IR). Treatment with Chir-124 resulted in reduced clonogenic survival and abrogated the IR-induced G(2)-M arrest in a panel of isogenic HCT116 cell lines after IR. This radiosensitizing effect was relatively similar between p53(-/-) and p53-sufficient wild type (WT) HCT116 cells. However, the number of mitotic cells (as measured by assessing the phosphorylation of mitotic proteins) increased dramatically in p53(-/-) HCT116 cells after concomitant Chir-124 exposure, compared to IR alone, while no such effect was observed in p53-sufficient WT HCT116 cells. In p53(-/-) cells, Chir-124 treatment induced a marked accumulation of polyploid cells that were characterized by micronucleation or multinucleation. p21(-/-) HCT116 cells displayed a similar pattern of response as p53(-/-) cells. Chir-124 was able to radiosensitize HCT116 cells that lack checkpoint kinase-2 (CHK2) or that were deficient for the spindle checkpoint protein Mad2. Finally, Chir-124 could radiosensitize tetraploid cell lines, which were relatively resistant against DNA damaging agents. Altogether these results suggest that Chir-124-mediated radiosensitization is profoundly influenced by the p53 and cell cycle checkpoint system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305158     DOI: 10.4161/cc.8.8.8203

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  30 in total

1.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.

Authors:  J-J Lee; B C Kim; M-J Park; Y-S Lee; Y-N Kim; B L Lee; J-S Lee
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 3.  Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.

Authors:  David R Raleigh; Daphne A Haas-Kogan
Journal:  Future Oncol       Date:  2013-02       Impact factor: 3.404

4.  Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy.

Authors:  Céline Clémenson; Cyrus Chargari; Laurent Désiré; Anne-Sophie Casagrande; Jean Bourhis; Eric Deutsch
Journal:  Invest New Drugs       Date:  2012-01-14       Impact factor: 3.850

5.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Authors:  Linda S Steelman; Patrick Navolanic; William H Chappell; Stephen L Abrams; Ellis W T Wong; Alberto M Martelli; Lucio Cocco; Franca Stivala; Massimo Libra; Ferdinando Nicoletti; Lyudmyla B Drobot; Richard A Franklin; James A McCubrey
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

6.  The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Authors:  Remko Prevo; Emmanouil Fokas; Philip M Reaper; Peter A Charlton; John R Pollard; W Gillies McKenna; Ruth J Muschel; Thomas B Brunner
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

7.  Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

Authors:  Sean Vance; Erqi Liu; Lili Zhao; Joshua D Parsels; Leslie A Parsels; Jeffery L Brown; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

8.  3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.

Authors:  Chong Yang; Ping Fan; Shikai Zhu; Hongji Yang; Xin Jin; Heshui Wu
Journal:  Oncol Lett       Date:  2018-03-28       Impact factor: 2.967

9.  Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.

Authors:  Madhav Sankunny; Rahul A Parikh; Dale W Lewis; William E Gooding; William S Saunders; Susanne M Gollin
Journal:  Genes Chromosomes Cancer       Date:  2013-11-25       Impact factor: 5.006

Review 10.  Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.

Authors:  Shih-Hung Yang; Ting-Chun Kuo; Hsu Wu; Jhe-Cyuan Guo; Chiun Hsu; Chih-Hung Hsu; Yu-Wen Tien; Kun-Huei Yeh; Ann-Lii Cheng; Sung-Hsin Kuo
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.